Journal Mobile Options
Table of Contents
Vol. 209, No. 4, 2004
Issue release date: 2004
Dermatology 2004;209:291–295

Idiopathic Systemic Capillary Leak Syndrome: Cutaneous Involvement Can Be Misleading

Fardet L. · Kerob D. · Rybojad M. · Vignon-Pennamen M.D. · Schlemmer B. · Guermazi A. · Morel P. · Lebbé C.
Departments of aDermatology, bPathology and cIntensive Care, Centre Hospitalier Universitaire Saint-Louis, Paris, France; dDepartment of Radiology, University of California, San Francisco, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Systemic capillary leak syndrome (SCLS) is a severe disorder characterized by unexplained rapid transfer of considerable volumes of plasma from the intravascular to the extravascular compartment. For some cases of SCLS, no aetiology is evident and these cases are reported as idiopathic (ISCLS). Objectives: To describe the cutaneous findings in 3 patients with ISCLS. Results: Cutaneous involvement consisted in sclerosis, livedo, purpura and photodistributed maculopapular erythematous rash. Dermal mucinosis was proven by biopsy in 1 patient. No underlying disease was diagnosed during follow-up. Conclusion: The above-mentioned cutaneous findings can be present during acute attacks of ISCLS. They seem specifically related to the ISCLS and not indicative of an underlying disease.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Ishihara H, Matsui A, Muraoka M, Tanabe T, Tsubo T, Matsuki A: Detection of capillary protein leakage by indocyanine green and glucose dilutions in septic patients. Crit Care Med 2000;28:620–626.
  2. Marx G, Vangerow B, Burczyk C, et al: Evaluation of noninvasive determinants for capillary leakage syndrome in septic shock patients. Intensive Care Med 2000;26:1252–1258.
  3. Nurnberger W, Willers R, Burdach S, Gobel U: Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann Hematol 1997;74:221–224.
  4. Funke I, Prummer O, Schrezenmeier H, et al: Capillary leakage syndrome associated with elevated IL-2 serum levels after allogenic BMT. Ann Haematol 1993;68:49–52.
  5. Al-Homaidhi A, Prince HM, Al-Zahrani H, Doucette D, Keating A: Granulocyte-macrophage colony-stimulating factor-associated histiocytosis and capillary-leak syndrome following autologous bone marrow transplantation: Two case reports and a review of the literature. Bone Marrow Transplant 1998;21:209–214.
  6. Cotran RS, Pober JS, Gimbrone MA Jr, et al: Endothelial activation during IL-2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 1988;140:1883–1888.
  7. Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 1986;137:1735–1738.
  8. Remick DG, Kunkel R, Larrick JW, Kunkel SL: Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest 1987;56:583–590.
  9. Zhang W, Ewan PW, Lachmann PJ: The paraproteins in systemic capillary leak syndrome. Clin Exp Immunol 1993;93:424–429.
  10. Piette AM, de Rohan-Chabot P, Chapman A, Gepner P, Brenot F, Loirat P: Choc hypovolémique par augmentation de la perméabilité capillaire associé à une gammapathie monoclonale. Ann Méd Interne 1985;136:572–574.
  11. Clarkson B, Thompson D, Horwith M, Luckey EH: Cyclical edema and shock due to increased capillary permeability. Am J Med 1960;29:193–216.
  12. Amoura Z, Papo T, Ninet J, et al: Systemic capillary leak syndrome: Report on 13 patients with special focus on course and treatment. Am J Med 1997;103:514–519.
  13. Janin-Manificat L, Martelet M, Guy H, Besancenot JF, Cortet P: Choc hypovolémique par augmentation de la perméabilité capillaire: un cas sans dysglobulinémie monoclonale. Nouv Presse Méd 1982;11:2716.
  14. Teelucksingh S, Padfield PL, Edwards CR: Systemic capillary leak syndrome. Q J Med 1990;75:515–524.
  15. Atkinson JP, Waldmann TA, Stein SF, et al: Systemic capillary leak syndrome and monoclonal IgG gammapathy: Studies in a sixth patient and review of the literature. Medicine 1977;56:225–239.
  16. Barnadas MA, Cistero A, Sitjas D, Pascual E, Puig X, de Moragas J: Systemic capillary leak syndrome. J Am Acad Dermatol 1995;32:364–366.
  17. Dolberg-Stolik OC, Putterman C, Rubinow A, Rivkind AI, Sprung CL: Idiopathic capillary leak syndrome complicated by massive rhabdomyolysis. Chest 1993;104:123–126.
  18. Cicardi M, Gardinali M, Bisiani G, Rosti A, Allavena P, Agostoni A: The systemic capillary leak syndrome: Appearance of interleukin-2-receptor-positive cells during attacks. Ann Intern Med 1990;113:475–477.
  19. Wolkenstein P, Chosidow O, Wechsler J, et al: Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma. J Am Acad Dermatol 1993;28:66–70.
  20. Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI: Dermatologic changes associated with interleukin 2 administration. JAMA 1987;258:1624–1629.
  21. Larbre B, Nicolas JF, Sarret Y, Tognet E, Mercatello A, Thivolet J: Immunothérapie par interleukin-2 et manifestations cutanées. Ann Dermatol Vénéréol 1993;120:528–533.
  22. Eeckout I, Vogelaers D, Geerts ML, Naeyaert JM: Xanthomas due to generalized oedema. Br J Dermatol 1997;136:601–603.
  23. el Wady Z, Bagot M, Wechsler J, et al: Syndrome de fuite capillaire révélant un lymphome T diffus mixte. Ann Dermatol Vénéréol 1991;118:882–883.
  24. Dereure O, Portales P, Clot J, Guilhou JJ: Biclonal Sézary syndrome with capillary leak syndrome. Dermatology 1994;188:152–156.
  25. Carsuzaa F, Pierre C, Morand JJ, Farnarier C, Marrot F, Kaplanski G: Syndrome de fuite capillaire révélant une papulo-érythrodermie d’Ofuji. Ann Dermatol Vénéréol 1996;123:559–562.
  26. McGregor JM, Barker JN, MacDonald DM: Pulmonary capillary leak syndrome complicating generalized pustular psoriasis: Possible role of cytokines. Br J Dermatol 1991;125:472–474.
  27. O’Donnell PG, Hughes JR, Higgins EM, Groves RW, Pembroke AC: A fatal case of capillary leak syndrome in erythrodermic psoriasis. Br J Dermatol 1995;132:160–161.
  28. Rauzy O, Adoue D, Arlet P: Chronic systemic capillary leak syndrome not requiring treatment? Am J Med 1998;105:360.
  29. Kao NL, Wendell Richmond G, Luskin AT: Systemic capillary leak syndrome. Chest 1993;104:1637–1638.
  30. Stirling CM, Boulton-Jones JM, Simpson K: Progressive oedema in a 30-year-old. Lancet 1998;352:450.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50